Lumida
/URGN
⌘K
Urogen Pharma Ltd

Urogen Pharma Ltd

URGN
$42.31USD+0.17%+0.07 today

MARKET CAP

2.1B

P/E (TTM)

FWD P/E

DAY RANGE

$42 – $44

52W RANGE

$16
$51

AI Summary

Stalk
Sell NowMedium

URGN has resumed a Stage 4 downtrend, driven by the Post-Parabola Collapse pattern and declining EMAs. Medium-term bias is bearish as price makes lower highs and lows and remains below the 9- and 20-day EMAs. Short-term momentum is negative, with price failing at near-term resistance and tracking lower. The momentum-oriented strategy favors continuation participation on rallies into the 9/20 EMA resistance zone (~44.8–45). Initiate Sell Now into that area and avoid chasing further declines.

  • Q2 revenue forecast of $62.8M, marking sequential top-line growth
  • EPS loss narrowing to $0.28 indicates improving financial momentum
  • Sustained $0.28 EPS loss underscores persistent profitability challenges
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$48.0M$64.4M$82.7M$90.4M$109.8M
YoY %+307.2%+34.0%+28.5%+9.3%+21.4%
P / Sales4.4x3.1x5.3x5.1x10.3x
EV / Sales5.8x5.7x7.1x6.4x12.0x
Gross Profit, Adj.$42.9M$48.3M$73.4M$81.5M$97.3M
YoY %+297.5%+12.5%+52.0%+11.1%+19.4%
Margin %89.3%75.0%88.7%90.2%88.7%
EV / Gross Profit6.5x7.6x8.0x7.1x13.6x
EBITDA, Adj.$-91.5M$-85.7M$-64.7M$-96.5M$-124.6M
YoY %+26.7%+6.3%+24.4%-49.0%-29.1%
Margin %-190.4%-133.1%-78.3%-106.7%-113.5%
EV / EBITDA-3.1x-4.3x-9.1x-6.0x-10.6x
EBIT$-92.3M$-87.5M$-65.5M$-96.8M$-124.9M
YoY %+27.2%+5.2%+25.1%-47.7%-29.0%
Margin %-192.1%-135.9%-79.2%-107.1%-113.7%
EV / EBIT-3.0x-4.2x-9.0x-6.0x-10.6x
Net Income$-110.8M$-109.8M$-102.2M$-126.9M$-153.5M
YoY %+13.7%+0.9%+6.9%-24.1%-21.0%
Net Margin-230.7%-170.6%-123.6%-140.4%-139.8%
EPS (GAAP)-$4.96-$4.81-$3.55-$2.96-$3.19
YoY %+15.9%+3.0%+26.2%+16.6%-7.8%